Open AccessBlood circulating tumor DNA for non‐invasive genotyping of colon cancer patients
Author(s) -
Siravegna Giulia,
Bardelli Alberto
Publication year - 2016
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1016/j.molonc.2015.12.005
Subject(s) - liquid biopsy , colorectal cancer , genotyping , minimal residual disease , medicine , cell free fetal dna , biopsy , circulating tumor dna , drug resistance , oncology , disease , cancer , cancer research , pathology , biology , genotype , gene , genetics , pregnancy , fetus , prenatal diagnosis , leukemia
Most solid tumors, including colorectal cancers, shed cell‐free DNA (ctDNA) in the blood. ctDNA can be analyzed to generate molecular profiles which capture the heterogeneity of the disease more comprehensively then tumor tissue biopsies. This approach commonly called ‘liquid biopsy’ can be applied to monitor response to therapy, to assess minimal residual disease and to uncover the emergence of drug resistance. This review will discuss current and future developments of ctDNA analysis in the clinical management of colorectal cancer patients.